Wayne, New Jersey
Dr. Tycho Heimbach is a Director at Novartis where he leads a global PBPK modeling group in PK Sciences and serves as PBPK and biopharmaceutics expert. He currently chairs a global team which reviews and makes recommendations and conducts predictions to inform PBPK formulation selections and design special populations trials within the global PK Sciences function. His responsibilities include addressing regulatory questions in pediatric drug development. Moreover, his duties include development of translational biopharmaceutic formulation and PBPK/PD strategies across all disease areas. He served as the Novartis representative on the PBPK International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).
Dr. Heimbach contributed to a priori PBPK modeling for 20+clinical trials and has authored/coauthored 15+ IND’s. Since 2009 he has been a leader in the prediction of pharmacokinetics and absorption for human trials. He also serves as an expert to guide prodrug strategies to improve drug targeting and a IQ food-effect expert member.
Dr. Heimbach has been a speaker at 25 national and international conferences. He has authored/coauthored 25 peer-reviewed publications, 3 book chapters and 1 patent.
Dr. Heimbach has significant AAPS volunteer history as an elected PDD/PPB officer (2008-2015), and as AAPS Ambassador (2017-current).